Taiwan Advance Bio-Pharmaceutical's quarterly market cap
declined
from Dec. 2024 (NT$1,417.5 Mil) to Jun. 2025 (NT$1,017.0 Mil) and
declined
from Jun. 2025 (NT$1,017.0 Mil) to Dec. 2025 (NT$1,003.5 Mil).
Taiwan Advance Bio-Pharmaceutical's annual market cap
declined
from Dec. 2023 (NT$1,525.5 Mil) to Dec. 2024 (NT$1,417.5 Mil) and
declined
from Dec. 2024 (NT$1,417.5 Mil) to Dec. 2025 (NT$1,003.5 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Taiwan Advance Bio-Pharmaceutical's Enterprise Value for Today is NT$1,041.0 Mil.
Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Taiwan Advance Bio-Pharmaceutical Market Cap Related Terms
Taiwan Advance Bio-Pharmaceutical Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Advance Bio-Pharmaceutical Market Cap Chart
ROCO:4186 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Taiwan Advance Bio-Pharmaceutical's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Advance Bio-Pharmaceutical Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taiwan Advance Bio-Pharmaceutical's Market Cap distribution charts can be found below:
* The bar in red indicates where Taiwan Advance Bio-Pharmaceutical's Market Cap falls into.
Taiwan Advance Bio-Pharmaceutical Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Advance Bio-Pharmaceutical (ROCO:4186) has a Market Cap of NT$909.0 Mil as of Jul. 06, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Taiwan Advance Bio-Pharmaceutical and its competitors. According to the industry distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #1027 out of 1422 companies in the Biotechnology industry, placing it in the top 72.2%.
Is Taiwan Advance Bio-Pharmaceutical's Market Cap too high?
Taiwan Advance Bio-Pharmaceutical's current Market Cap is NT$909.0 Mil. Based on the distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #1027 out of 1422 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Taiwan Advance Bio-Pharmaceutical has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Taiwan Advance Bio-Pharmaceutical's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #1027 out of 1422 companies for Market Cap. This places Taiwan Advance Bio-Pharmaceutical in the lower half of its industry. The industry median Market Cap is 121.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.26, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Taiwan Advance Bio-Pharmaceutical and its competitors. For the Biotechnology industry, the median Market Cap is 121.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Advance Bio-Pharmaceutical's current Market Cap is NT$909.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Advance Bio-Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical (ROCO:4186) is currently considered Possible Value Trap. The stock's GF Value™ is NT$17.88, compared to a current price of NT$10.10 — trading 43.5% below its estimated fair value. The current Market Cap is NT$909.0 Mil. Taiwan Advance Bio-Pharmaceutical's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Taiwan Advance Bio-Pharmaceutical (ROCO:4186), the current Market Cap is NT$909.0 Mil as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical stock appears to be undervalued.
The current stock price of NT$10.10 is trading 43.5% below its estimated GF Value™ of NT$17.88.
GuruFocus considers Taiwan Advance Bio-Pharmaceutical to be Possible Value Trap.
Key valuation signals for ROCO:4186:
Market Cap: NT$909.0 Mil
GF Value™: NT$17.88 vs. price of NT$10.10 (43.5% below fair value)
No single metric tells the full story. See the ROCO:4186 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Advance Bio-Pharmaceutical Business Description
Taiwan Advance Bio-Pharmaceutical Inc operates in the food safety industry. The company's products include a Food safety test kit, Animal test kit, Pesticide test kit, Mycotoxin test kit, Nuleic acid extraction kit.
52GF Score
Get the complete analysis for ROCO:4186
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4186 has been successfully added to your 
